Scholars Central

Conference abstractPublished 4 Aug 2015

Drug development targeting cancer stem cells

Authors: Angel Garcia Martin

StemTek, Therapeutics, Spain

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Conventional anti-cancer treatment excels at tumor size reduction leading to clinically evident responses. However, these effects are frequently transient and are not associated with increased patient survival. Treatments are often too toxic to normal cells and they fail to selectively kill cancer stem cells (CSCs), which can survive treatment and, like the queen bee of a beehive, give rise to new malignant cells. Therefore CSCs are an underlying cause of tumor recurrence and metastasis. For truly effective treatments that can create a durable clinical response drugs that can target CSCs must be developed. Here we present data showing how functional assays for drug screening may be used to unravel compounds that target cancer stem cells, with a case study on drugs that inhibit activation of HIF dependent pathways

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectGenetics & Molecular Biology
  • SubjectOncology & Cancer
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Angel Garcia Martin”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels